Top Markets
Coin of the day
Kyverna Therapeutics, Inc. Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc.

KYTX
Rank in Stocks #13175
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Share Price
$8.46
Last synced: 2026-08-28
Market Cap
$514.33M
Change (1 day)
-2.08%
Change (1 year)
128.03%
Country
US
Trade Kyverna Therapeutics, Inc. (KYTX)

Category

Stock price history for Kyverna Therapeutics, Inc. (KYTX)
Highest end of day price: $8.33 on 2026-08-01

Lowest end of day price: $28.70 on 2024-02-01
Stock price history of Kyverna Therapeutics, Inc. from 2024 to 2026
Annual Stock Price Performance
Year Performance
2026 (TTM) -5.16%
2025 89.56%
2024 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.01 -13.08%
AU
$138.18 473.58%
US
$753.02 6.32%
CH